TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Cantargia AB ( (SE:CANTA) ) has shared an update.
Cantargia AB announced that the TRIFOUR study, evaluating nadunolimab in triple-negative breast cancer, showed no difference in median overall survival between the treatment and control groups, both achieving a survival duration of 26 months. Despite the study not meeting its objectives, Cantargia sees potential in nadunolimab for pancreatic cancer, emphasizing the trial’s insights and the drug’s promising efficacy in other cancer types.
The most recent analyst rating on (SE:CANTA) stock is a Buy with a SEK14.00 price target. To see the full list of analyst forecasts on Cantargia AB stock, see the SE:CANTA Stock Forecast page.
More about Cantargia AB
Cantargia AB is a biotechnology company focused on developing antibody-based treatments for life-threatening diseases, utilizing a platform centered on the protein IL1RAP. The company is primarily engaged in oncology, with its lead product nadunolimab (CAN04) being studied in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Cantargia also has a program for autoimmune and inflammatory diseases with its antibody CAN10.
Average Trading Volume: 3,087,456
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.1B
Find detailed analytics on CANTA stock on TipRanks’ Stock Analysis page.